COVID-19 and virus-associated skin diseases in patients after kidney transplantation

Background: COVID-19 in solid organ transplant recipients is usually characterized by a more severe disease course and is often associated with life-threatening complications. Identification of additional factors that may affect the risk and severity of the new coronavirus infection could have a significant impact on choosing a management strategy for renal graft recipients. Aim: to evaluate the possibility of cross-immunity between skin manifestations of viral etiology and COVID-19. Materials and methods: from May 2020 to February 2021 we examined 180 renal graft recipients with a history of transplantation from 2 months to 26.5 years. All patients were categorized into two groups: group I, those who had confirmed moderate or severe COVID-19 disease, and group II, and those without any history of clinical manifestations of the new coronavirus infection (including those with potentially asymptomatic disease). During the study period which lasted for 71 months on average (range, 2 to 318 months), laboratory workup was performed on all patients (on average, twice): dermatological examination and detection of serum antibodies to herpes simplex virus 1, 2, cytomegalovirus, Epstein-Barr virus, COVID-19. Results: in recipients with HPV-associated skin manifestations, the incidence of COVID-19 was significantly lower than in recipients who did not have them: - 30.4% and 50%, respectively, p=0.011. The incidence of new coronavirus infection did not differ in the groups of patients with cutaneous manifestations caused by herpes simplex viruses type 1 and 2 and without them. Among recipients with Epstein-Barr virus seropositivity, there were significantly fewer cases of COVID-19 compared to seronegative patients - 26.2% and 54.8%, respectively, p=0.0002. Conclusion: HPV-associated dermal manifestations of serum EBV-seropositivity in recipients after kidney transplantation is associated with a lower incidence of moderate and severe COVID-19. Further studies are needed to confirm the possibility of cross-immunity against COVID-19 with other infections.

COVID-19, пересадка почки, вирус папилломы человека (ВПЧ), вирус Эпштейн-Барра, COVID-19, kidney transplantation, human papillomavirus, Epstein-Barr virus

1. Shingare A., Bahadur M.M., Raina S. COVID-19 in recent kidney transplant recipients. Am J Transplant. 2020; 20(11): 3206-3209. doi: 10.1111/ajt.16120.

2. Akalin E., Azzi Y., Bartash R., et al. COVID-19 and Kidney Transplantation. N Engl J Med. 2020; 382(25): 2475-2477. doi: 10.1056/NEJMc2011117.

3. Zhang H., Chen Y., Yuan Q. et al. Identification of Kidney Transplant Recipients with Coronavirus Disease 2019. Eur Urol. 2020; 77(6): 742-747. doi: 10.1016/j.eururo.2020.03.030.

4. Banerjee D., Popoola J., Shah S. et al. COVID-19 infection in kidney transplant recipients. Kidney Int. 2020; 97(6): 1076-1082. doi: 10.1016/j.kint.2020.03.018.

5. Imam A., Abukhalaf S.A., Imam R. et al. Kidney Transplantation in the Times of COVID-19 - A Literature Review. Ann Transplant. 2020; 25: e925755. doi: 10.12659/AOT.925755.

6. Gandolfini I., Delsante M., Fiaccadori E. et al. COVID-19 in kidney transplant recipients. Am J Transplant. 2020; 20(7): 1941-1943. doi: 10.1111/ajt.15891.

7. Castells M.C., Phillips E.J. Maintaining Safety with SARS-CoV-2 Vaccines. N Engl J Med. 2021; 384(7): 643-649. doi: 10.1056/NEJMra2035343.

8. Agrawal B. Heterologous immunity: Role in natural and vaccine-induced resistance to infections. Front Immunol. 2019; 10: 2631. doi: 10.3389/fimmu.2019.02631.

9. Welsh R.M., Fujinami R.S. Pathogenic epitopes, heterologous immunity and vaccine design. Nat Rev Microbiol. 2007; 5(7): 555-563. doi: 10.1038/nrmicro1709.

10. Che J.W., Selin L.K., Welsh R.M. Evaluation of non-reciprocal heterologous immunity between unrelated viruses. Virology. 2015; 482: 89-97. doi: 10.1016/j.virol.2015.03.002.

11. Mathurin K.S., Martens G.W., Kornfeld H., Welsh R.M. CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses. J Virol. 2009; 83(8): 3528-3539. doi: 10.1128/JVI.02393-08.

12. Reche P.A. Potential cross-reactive immunity to SARS-CoV-2 from common human pathogens and vaccines. Front Immunol. 2020; 11: 586984. doi: 10.3389/fimmu.2020.586984.

13. Российское общество дерматовенерологов и косметологов. Федеральные клинические рекомендации по ведению больных вирусными бородавками. М.; 2015. 13 с. Доступно на: https://www.ismos.ru/guidelines/doc/virusnye_borodavki.pdf

14. Andersson K., Waterboer T., Kirnbauer R. et al. Seroreactivity to cutaneous human papillomaviruses among patients with nonmelanoma skin cancer or benign skin lesions. Cancer Epidemiol Biomarkers Prev. 2008; 17(1): 189-195. doi: 10.1158/1055-9965.EPI-07-0405.